Table 3.
Characteristics | P value | HR | 95% CI for HR |
---|---|---|---|
Age at diagnosis | |||
40–44 years | Reference | ||
45–49 years | 0.542 | 0.932 | 0.741–1.170 |
50–54 years | 0.878 | 1.017 | 0.821–1.260 |
55–59 years | 0.024 | 1.270 | 1.032–1.562 |
Race | |||
White | Reference | ||
Black | 0.001 | 1.317 | 1.127–1.540 |
Other a | 0.128 | 1.192 | 0.951–1.495 |
Marital status | |||
Single | Reference | ||
Married | 0.008 | 0.819 | 0.707–0.949 |
Other b | 0.130 | 0.871 | 0.728–1.042 |
Insurance (yes vs no) | < 0.001 | 0.587 | 0.459–0.751 |
Histology | |||
Ductal | Reference | ||
Lobular | 0.744 | 1.041 | 0.820–1.321 |
Others | 0.356 | 1.105 | 0.894–1.365 |
Laterality | |||
Right | Reference | ||
Left | 0.506 | 1.043 | 0.921–1.182 |
Bilateral, single primary | 0.177 | 2.21 | 0.894–1.365 |
Grade | |||
I | Reference | ||
II | 0.309 | 1.147 | 0.881–1.492 |
III or IV | < 0.001 | 1.960 | 1.491–2.577 |
Tumour subtype | |||
HR+/HER2- | Reference | ||
HR+/HER2+ | 0.002 | 0.631 | 0.474–0.839 |
HR−/HER2- | < 0.001 | 2.808 | 2.169–3.634 |
HR−/HER2+ | 0.258 | 0.716 | 0.401–1.277 |
Site of metastases | |||
Lung (yes vs no) | 0.020 | 1.378 | 1.188–1.598 |
Liver (yes vs no) | < 0.001 | 2.085 | 1.795–2.422 |
Brain (yes vs no) | < 0.001 | 1.903 | 1.542–2.248 |
Surgery (yes vs no) | < 0.001 | 0.504 | 0.431–0.590 |
HR+/HER2- * multi-metastases | Reference | ||
HR+/HER2+ * multi-metastases | 0.045 | 0.694 | 0.485–0.992 |
HR−/HER2- * multi-metastases | 0.717 | 0.941 | 0.675–1.310 |
HR−/HER2+ * multi-metastases | 0.564 | 0.828 | 0.437–1.572 |
Next step | |||
White*HR+/HER2- | Reference | ||
Black*HR+/HER2+ | 0.366 | 0.821 | 0.536–1.258 |
Other a*HR+/HER2+ | 0.652 | 0.862 | 0.453–1.641 |
Black*HR−/HER2- | 0.323 | 0.817 | 0.546–1.220 |
Other a*HR−/HER2- | 0.299 | 1.508 | 0.695–3.271 |
Black*HR−/HER2+ | 0.696 | 0.881 | 0.466–1.664 |
Other a*HR−/HER2+ | 0.368 | 0.701 | 0.323–1.521 |
Other a (American Indian/AK Native, Asian/Pacific Islander)
Other b (divorced/widowed/separated).